← back to search

Jason Fangusaro

Winship Cancer Institute · US
Area of research
Genetics · Neurology
Research interest
Research interests include Glioma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Brain Metastases and Treatment, and Neurofibromatosis and Schwannoma Cases.
h-index
44
citations
7,856
works
222
NIH funding
primary concept
Medicine
email

Recent publications

Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative Groups.
2026cited by 0position: contributordoi
Response Assessment in Pediatric Neuro-Oncology Symposium, Pediatric Society of Neuro-Oncology proceedings: Current status and future initiatives
Neuro-Oncology Pediatrics 2026cited by 0position: contributordoi
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4
Neuro-Oncology 2025cited by 10position: firstdoi
Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report
Neuro-Oncology 2025cited by 7position: middledoi
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report.
2025cited by 5position: contributordoi
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
2025cited by 4position: contributordoi
IMMU-79. An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13
Neuro-Oncology 2025cited by 0position: middledoi
DMG-65. The Diffuse Intrinsic Glioma (DIPG) and Diffuse Midline Glioma (DMG) National Brain Tumor Board: Review of Resource Implementation and Utilization
Neuro-Oncology Pediatrics 2025cited by 0position: middledoi
The DIPG/DMG National Tumor Board: The power of advocacy
Neuro-Oncology Pediatrics 2025cited by 0position: contributordoi
Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
2024cited by 59position: contributordoi
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions
Neuro-Oncology 2024cited by 23position: middledoi
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition
Neuro-Oncology 2024cited by 22position: middledoi
Towards consistency in pediatric brain tumor measurements: Challenges, solutions, and the role of artificial intelligence-based segmentation
Neuro-Oncology 2024cited by 21position: middledoi
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.
2024cited by 4position: contributordoi
LGG-05. REPORT ON PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-029B, A PROSPECTIVE PHASE 2 CLINICAL TRIAL OF SELUMETINIB IN TREATING YOUNG PATIENTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA: NEW RESULTS ON STRATA 2, 5, AND 6 WITH UPDATED LONG-TERM SURVIVAL OUTCOMES ON STRATA 1, 3, AND 4
Neuro-Oncology 2024cited by 2position: firstdoi
Pediatric low-grade glioma: State-of-the-art and ongoing challenges
Neuro-Oncology 2023cited by 82position: firstdoi
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
2023cited by 44position: contributordoi
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
Neuro-Oncology 2023cited by 41position: middledoi
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation
Neuro-Oncology 2023cited by 15position: middledoi
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group
Neuro-Oncology 2023cited by 9position: middledoi
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
2023cited by 9position: contributordoi
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
Neuro-Oncology 2022cited by 96position: middledoi
The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science
Neoplasia 2022cited by 89position: middledoi
Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors
JCO Precision Oncology 2022cited by 48position: middledoi
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
2022cited by 31position: contributordoi
Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials
Neuro-Oncology 2022cited by 21position: middledoi
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors
European Journal of Cancer 2022cited by 16position: middledoi
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group.
UCL Discovery (University College London) 2022cited by 15position: middledoi
A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors
International Journal of Radiation Oncology*Biology*Physics 2022cited by 15position: middledoi
Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials.
2022cited by 14position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Maryam Fouladi · University of Cincinnati19 papers (2013–2025)Arzu Onar‐Thomas · Cancer Research And Biostatistics15 papers (2013–2025) · 15 papers (2019–2026)Lindsay Kilburn · Columbia University Irving Medical Center11 papers (2017–2025)Ira J. Dunkel · National Cancer Institute10 papers (2017–2025)Shengjie Wu · St. Jude Children's Research Hospital9 papers (2013–2022)Roger J. Packer · Jefferson Hospital for Neuroscience9 papers (2013–2024)Girish Dhall · Children's of Alabama9 papers (2017–2022)Tina Young Poussaint · Boston Children's Hospital9 papers (2013–2025)Ibrahim Qaddoumi · Tennessee Oncology7 papers (2017–2025)Stewart Goldman · Phoenix College7 papers (2012–2022)Ian F. Pollack · University of Pittsburgh7 papers (2013–2025)Azra H. Ligon · Harvard University6 papers (2017–2025)Clinton F. Stewart · University of Tennessee Health Science Center6 papers (2017–2025)Michael J. Fisher · Stanford Medicine6 papers (2020–2024)Ute Bartels · Institute for Clinical Evaluative Sciences5 papers (2019–2022)Nathan Robison · University of Southern California5 papers (2020–2025)Soumen Khatua · The University of Texas Health Science Center at Houston5 papers (2019–2022)Sridharan Gururangan · Deltagen (United States)5 papers (2013–2025)David Jones · Mayo Clinic in Florida5 papers (2020–2025)